Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
First-line molecular therapies in the treatment of metastatic colorectal cancer-A literature-based review of phases II and III trials
Arndt Vogel
*
,
Martha M. Kirstein
*
Corresponding author for this work
Clinic of Internal Medicine I
Hannover Medical School
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'First-line molecular therapies in the treatment of metastatic colorectal cancer-A literature-based review of phases II and III trials'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
100%
Neoplasm
80%
Vasculotropin
60%
Progression Free Survival
40%
Phase II Trials
20%
Vasculotropin A
20%
Irinotecan
20%
Colorectal Liver Metastasis
20%
Overall Survival
20%
Combination Therapy
20%
Oxaliplatin
20%
Fluoropyrimidine
20%
Long Term Survival
20%
Panitumumab
20%
Immunology and Microbiology
Epidermal Growth Factor
100%
Epidermal Growth Factor Receptor Antibody
60%
Progression Free Survival
40%
Cetuximab
20%
Panitumumab
20%
Overall Survival
20%
Long Term Survival
20%